BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

TVM Capital Healthcare invests in HiRO to accelerate Southeast Asia expansion

November 26, 2026 | News

To connect global sponsors with the region's large patient populations



China-based Harvest Integrated Research Organization (HiRO), a full-service global contract research organization (CRO) with more than 550 professionals operating across 23 countries in North America, Europe, Oceania and Asia, has received a strategic investment from Singapore's TVM Capital Healthcare's Southeast Asia Fund.

The investment will accelerate HiRO's expansion across Southeast Asia — one of the world's fastest-growing regions for clinical trial activity — building on the company's existing operational footprint to connect global sponsors with the region's large patient populations, currently underrepresented in global trials, through a single, integrated partner.

Southeast Asia represents one of the most compelling opportunities in global clinical development. The ASEAN member states are home to nearly 700 million people, including significant under-served populations across high-priority indications such as first-line lung, liver and breast cancers, chronic hepatitis B and type 2 diabetes — patient populations that are both clinically important and increasingly difficult to access in saturated Western markets.

TVM Capital Healthcare's investment will enable HiRO to transform its existing Southeast Asia operations into a full-scale acceleration platform for global sponsors. Faster patient enrolment compresses clinical timelines, shortens the path to the pivotal data that investors fund and that acquirers and licensing partners value — and, critically, brings life-changing therapies to patients who need them sooner.